About Us

Novel treatment for iron-deficiency anemia

Fe3 is an early stage company developing a novel transdermal therapy for the treatment of iron deficiency anemia. The approach and technology for Fe3 was developed at InCube Labs, a multi-disciplinary life sciences R&D lab focused on developing breakthrough medical innovations.

Fe3, has developed a novel treatment for iron-deficiency anemia, a disorder which affects more than 14M women in the US alone.  The most common treatment for these women is an oral iron supplement; however, nearly half of these patients cannot tolerate oral iron due to nausea, constipation and other gastrointestinal adverse effects.

We have developed a disposable transdermal patch that requires minimal preparation and is gentle on the skin. Worn overnight once a week, the Fe3 patch delivers the amount of iron needed directly through the skin, bypassing the GI tract and eliminating undesirable side effects.

As a result, our therapy has the potential to significantly improve the patient experience and increase patient compliance.

We have significant pre-clinical and market research data and are planning for clinical trials.